Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05907499

Decitabine for Poor Graft Function Post Allo-HSCT

Conditions: Poor Graft Function

Sex: All
Ages: 16 Years – 70 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 76
Sponsor: The First Affiliated Hospital of Soochow University

Location: The First Affiliated Hospital of Soochow University Suzhou Jiangsu

Summary

This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.

Eligibility Criteria

Inclusion Criteria: 1. Diagnosed as PGF at day 28 post-HSCT or later. PGF was defined as two or three cytopenias, absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 30 × 109/L, hemoglobin ≤ 85g/L, lasting for more than 2 consecutive weeks; 2. Full donor chimerism; 3. Primary disease in remission; 4. No severe GVHD and relapse; 5. ECOG: 0-2; 6. Expected survival longer than 1 month Exclusion Criteria: 1. Allergic to decitabine; 2. Active infections; 3. Uncontrolled GVHD; 4. Severe organ dysfunction; 5. Relapse of underlying malignancies; 6. Graft failure; 7. Received decitabine or participated in other clinical trials within one month before screening.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05907499). StuddyBuddy aggregates publicly available trial information.